CAS 292168-79-7

Formule : C14H10N4O3S

InChI : InChI=1S/C14H10N4O3S/c19-13-12(15-14(22)16-13)8-11-2-1-7-17(11)9-3-5-10(6-4-9)18(20)21/h1-8H,(H2,15,16,19,22)/b12-8-

Code InChI : FMLUAKSJMUPACD-WQLSENKSSA-N

SMILES : C1=CN(C(=C1)/C=C\2/C(=O)NC(=S)N2)C3=CC=C(C=C3)[N+](=O)[O-]

KY1220

CAS : 292168-79-7

KY1220 destabilizes both β-catenin and Ras by targeting the Wnt/β-catenin pathway. It has an IC50 of 2.1 μM in HEK293 reporter cells.

Formule : C₁₄H₁₀N₄O₃S

Degré de pureté : 99.9%

Couleur et forme : Yellow Solid

Masse moléculaire : 314.32

Ref: TM-T15677

KY1220

CAS : 292168-79-7

Formule : C₁₄H₁₀N₄O₃S

Degré de pureté : 98%

Couleur et forme : Solid

Masse moléculaire : 314.3192

Ref: IN-DA01EB20

KY1220

CAS : 292168-79-7

KY1220

Formule : C₁₄H₁₀N₄O₃S

Degré de pureté : ≥98%

Masse moléculaire : 314.32

Ref: 54-BUP09774

KY1220

CAS : 292168-79-7

5-((1-(4-Nitrophenyl)-1H-pyrrol-2-yl)methylene)-2-thioxoimidazolidin-4-one

Formule : C₁₄H₁₀N₄O₃S

Degré de pureté : 99%

Masse moléculaire : 314.32

Ref: IN-DG768297

KY1220

CAS : 292168-79-7

KY1220 is a molecule that destabilizes the activated state of PD-L1, which is a regulatory protein. KY1220 has been shown to enhance the effect of cancer cell death and inhibit metastatic colorectal cancer in mice. It was also found to be more effective than PD-L1 antibodies in reducing tumor size and inhibiting tumor growth. KY1220 has been shown to synergistically enhance the cytotoxic effects of other chemotherapeutic drugs on cancer tissues. This drug may be useful for treating patients with metastatic colorectal cancer or those who are resistant to PD-L1 antibodies.

Formule : C₁₄H₁₀N₄O₃S

Degré de pureté : Min. 95%

Masse moléculaire : 314.32 g/mol

Ref: 3D-SLA16879